Merck KGaA’s Oschmann: Pfizer Deal Likely A One Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck KGaA’s exclusive partnering deal with Pfizer to jointly develop and commercialize the German conglomerate’s key early pipeline asset will not be a model for other collaborations, as the group’s deputy CEO-elect says it wants to progress remaining early assets alone.